About CN Bio

Our Objective

Consumer goods, chemical companies and regulators use our microphysiological (MPS) systems and consumables to analyze novel compounds, assessing toxicity and safety in cells and organ models.

We also support research scientists who need data-rich in vitro studies to investigate a wide range of biological processes in fields including  oncology, infectious diseases, metabolism and inflammation.  

Our technologies enable researchers to work on innovative modalities including gene editing, therapeutic antibodies/proteins and cellular therapies.

Drug Discovery Technology

CN Bio’s MPS (also known as Organ-on-Chip) devices are designed to bring precision and human-relevant data to drug development and other commercial or research scenarios.

We work closely with leading academic bio-engineering groups including MIT (Massachusetts Institute of Technology) and Vanderbilt University. CN Bio has been awarded numerous prestigious grants by sponsors including Innovate UK and was a participant in the DARPA (United States Defence Advanced Research Projects agency) Organ-on-Chip project.

Our technology is being used by scientists at the US FDA (Food and Drug Administration) to investigate drug metabolism, toxicity and drug-drug interactions.

Predictive Drug Discovery

For preclinical drug development, our MPS platform, PhysioMimix ™, provides valuable predictive analytics and guidance when evaluating new drugs:

• Compatible with standard laboratory systems
• Detect potential side effects and toxicity markers before the drugs are tested in humans
  
• Predict whether a drug intended to treat one organ will have adverse effects on another
• Enhance or replace animal studies with more human-relevant in vitro models
• Explore diagnostic and precision medicine applications
• Assess a range of dosing options and combinations, in parallel in a single experiment

Systems Biology and Drug Repurposing

CN Bio has collaborated with a major pharmaceutical company to combine Organ-on-Chip models of fatty liver disease and non-alcoholic steatohepatitis (NASH) with computational systems biology. This approach can enable repurposing of drugs which have previously failed clinical trials but are known to be safe, tolerable and effective against their molecular target.